Pharmacokinetics of sparfloxacin and interaction with cisapride and sucralfate

Antimicrobial Agents and Chemotherapy

Volumn 41, Issue 8, 1997, Pages 1668-1672

  Zix, J A ^a   Geerdes Fenge, H F ^a   Rau, M ^a   Vockler J ^a   Borner, K ^a   Koeppe, P ^a   Lode, H ^a,b  

^a FREIE UNIVERSITÄT BERLIN   (Germany)

^b City Hospital Zehlendorf Heckeshorn   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CISAPRIDE; SPARFLOXACIN; SUCRALFATE;

ADULT; AGAR GEL DIFFUSION; AREA UNDER THE CURVE; ARTICLE; BACILLUS SUBTILIS; BIOASSAY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DRUG URINE LEVEL; GASTROINTESTINAL MOTILITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0030802462     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.41.8.1668     Document Type: Article

References (44)

1. Allain, P., Y. Mauras, N. Krari, J. Duchier, A. Cournot, and J. Larcheveque. 1990. Plasma and urine aluminium concentrations in healthy subjects after administration of sucralfate. Br. J. Clin. Pharmacol. 29:391-393.
2. Appelbaum, C. P. 1995. Comparative in vitro activity of sparfloxacin against organisms causing community acquired lower respiratory tract infections. Can. J. Infect. Dis. 6(Suppl. C) (abstr. 0108).
3. Averdunk, R., and K. Borner. 1970. Korrelation der Thromboplastinzeit bei Dicumarol-behandelten Patienten unter Verwendung verschiedener Thrombokinase-Präparate. Z. Klin. Chem. Klin. Biochem. 8:263-283.
4. Barry, A. L., and P. C. Fuchs. 1991. In vitro activities of sparfloxacin, tosufloxacin, ciprofloxacin, and fleroxacin. Antimicrob. Agents Chemother. 35:955-460.
5. Bateman, D. N. 1986. The action of cisapride on gastric emptying and the pharmacodynamics and pharmacokinetics of oral diazepam. Eur. J. Clin. Pharmacol. 30:205-208.
6. Borner, K., E. Borner, and H. Lode. 1992. Determination of sparfloxacin in serum and urine by high performance liquid chromatography. J. Chromatogr. 579:285-289.
7. Borner, K., E. Borner, and H. Lode. 1993. A metabolite of sparfloxacin in urine. Drugs 45:303-304.
8. Borner, K., H. Lode, G. Höffken, P. Koeppe, P. Olschewski, and B. Sievers. 1988. Comparative pharmacokinetics of ofloxacin and ciprofloxacin. Rev. Infect. Dis. 10(Suppl. 1):91-92.
9. Bran, S., W. A. Murray, I. B. Hirsch, and J. P. Palmer. 1995. Long QT syndrome during high-dose cisapride. Arch. Intern. Med. 155:765-768.
10. Deppermann, K. M., and H. Lode. 1993. Fluoroquinolones: interaction profile during enteral absorption. Drugs 45(Suppl. 3):65-72.
11. Eller, J., E. Tolksdorf, M. Rau, J. Vöckler, P. Koeppe, and H. Lode. 1995. Pharmacokinetics of loracabef and interaction with a prokinetic agent of the gastrointestinal tract, abstr. 4072. In Program and abstracts of the 19th International Congress of Chemotherapy. Can. J. Infect. Dis. 6(Suppl. 6).
12. Fisher, R. S. 1981. Sucralfate: a review of drug tolerance and safety. J. Clin. Gastroenterol. 3(Suppl. 2):181-184.
13. Garrelts, J. C., P. J. Godley, J. D. Peterie, E. H. Gerlach, and C. C. Yakshe. 1990. Sucralfate significantly reduces ciprofloxacin concentrations in serum. Antimicrob. Agents Chemother. 34:931-933.
14. Gehan, E. H., and S. L. George. 1970. Estimation of human body surface area from height and weight. Cancer Chemother Rep. 54:255.
15. Gutleben, K. J., J. Eller, M. Rau, J. Vöckler, P. Koeppe, J. Kottwas, and H. Lode. 1995. Pharmacokinetics of cefetamet pivoxil and interaction with cisapride and n-acetylcysteine, abstr 4073. In Program and abstracts of the 19th International Congress of Chemotherapy. Can. J. Infect. Dis. 6(Suppl. 6).
16. Hollander, D., and A. Tarnawski. 1990. The protective and therapeutic mechanisms of sucralfate. Scand. J. Gastroenterol. Suppl. 173:1-5.
17. Honeyburne, D., I. Greaves, D. R. Baldwin, J. M. Andrews, M. Harris, and R. Wise. 1994. The concentration of sparfloxacin in lung tissues after single and multiple oral doses. Int. J. Antimicrob. Agents. 4:151-155.
18. Jaillon, P., J. Morganroth, I. Brumpt, and G. Talbot. 1996. Overview of eletrocardiographic and cardiovascular safety data for sparfloxacin. J. Antimicrob. Chemother. 37(Suppl. A):161-167.
19. Johnson, J. H., M. A. Cooper, J. M. Andrews, and R. Wise. 1992. Pharmacokinetics and inflammatory fluid penetration of sparfloxacin. Antimicrob. Agents Chemother. 36:2444-2446.
20. Kawahara, S., A. Tada, H. Nagare, K. Takahashi and M. Kibata. 1995. Comparison of antimycobacterial activity of sparfloxacin and other new quinolones. Can. J. Infect. Dis. 6(Suppl. C) (abstr. 1169).
21. Kirch, W., H. D. Janisch, S. R. Santos, U. Duhrsen, P. Dylewicz, and E. E. Ohnhaus. 1986. Effect of cisapride and metoclopramide on digoxin bioaviability. Eur. J. Drug. Metab. Pharmacokinet. 11:249-250.
22. Kojima, G., M. Inoue, and S. Mitsuhashu. 1989. In vitro activity of AT4140 against clinical bacterial isolates. Antimicrob. Agents Chemother. 33:1980-1988.
23. Lecomte, S., C. Coupry, M. T. Chenon, and N. J. Moreau. 1993. Affinity of sparfloxacin and four other quinolones for magnesium and effect on antibacterial activity. Drugs 45(Suppl. 3):148-149.
24. Lewin, M. B., R. M. Bryant, A. L. Fenrich, and R. G. Grifka. 1996. Cisapride-induced long QT interval. J. Pediatr. 128:279-281.
25. Low, E. 1995. North American in vitro studies on sparfloxacin. Can. J. Infect. Dis 6(Suppl. C) (abstr. 0109).
26. Madsen, J. L. 1990. Effects of cisapride on gastrointestinal transit in healthy humans. Digest. Dis. Sci. 35:1500-1504.
27. Marshall, A. J. H., and L. J. V. Piddock. 1993. Effect of cations and EDTA upon the activity of 18 quinolones, gentamycin, ceftazidime, polymixin against gram negative and gram positive bacteria. Drugs 45(Suppl.3):150-151.
28. Mignot, A., M. J. Douin, L. Millerioux, D. Chassard, J. J. Thebault, G. Montay, and M. Ebmeier. 1990. Effect of aluminium hydroxide antacid on the pharmacokinetics of the new quinolone RP-64206, abstr. 1250, p. 294. In Program and abstracts of the 30th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
29. Montay, G., R. Bruno, J. C. Vergniol, M. Ebmeier, Y. Le Roux, C. Guimart, A. Frydman, D. Chassard, and J. J. Thebault. 1994. Pharmacokinetics of sparfloxacin in humans after single oral administration at doses of 200, 400, 600 and 800 mg. J. Clin. Pharmacol. 34:1071-1076.
30. Nakamura, S., A. Minami, and K. Nakatu. 1989. In vitro and in vivo activities of AT4140, a new broad-spectrum quinolone. Antimicrob. Agents Chemother. 33:1167-1173.
31. Nix, D. E., W. A. Watson, L. Handy, R. W. Frost. D. I. Rescott, and H. R. Goldstein. 1989. The effect of sucralfate pretreatment on the pharmacokinetics of ciprofloxacin. Pharmacotherapy 9:377-380.
32. Parpia, S. H., D. E. Nix, L. G. Hejmanowski, H. R. Goldstein, J. H. Wilton, and J. J. Schentag. 1989. Sucralfate reduces the gastrointestinal absorption of norfloxacin. Antimicrob. Agents Chemother. 33:99-102.
33. Peck, C. C., L. B. Sheiner, and A. I. Nichols. 1984. The problem of choosing weights in nonlinear regression analysis of pharmacokinetic data. Drug Metab. Rev. 15:133-148.
34. Quadri, S. M., Y. Ueno, J. J. Burns, E. Aldomovar, and N. Rabea. 1992. In vitro activity of sparfloxacin, a new broad-spectrum fluoroquinolone. Chemotherapy. (Basel 1) 38:99-106.
35. Reeves, D. S., and M. J. Bywater. 1976. Assay of antimicrobial agents, p. 21-78. In J. de Louvois (ed.), Selected topics in clinical bacteriology. Baillière & Tindall, London, United Kingdom.
36. Renau, T. E., J. W. Gaga, J. A. Dever, G. E. Roland, E. T. Joannides, M. A. Shapiro, S. A. Wold, S. J. Gracheck, J. M. Domagala, M. R. Jacobs, and R. C. Reynolds. 1996. Antituberculosis activity and side-effect profiles of 8 new quinolones optimized for antimycobacterial effects, abstr. F-210, p. 136. In Program and abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
37. Schwarz, G. 1978. Estimating the dimension of a model. Ann. Stat. 6:461-464.
38. Shimada, J., T. Nogita, and Y. Ishibashi. 1993. Clinical pharmacokinetics of sparfloxacin. Clin. Pharmacokinet. 25:358-369.
39. Tanimura, M., K. Ishimoto, H. Yukawa, Y. Sakamoto, and H. Onishi. 1991. Excretion into bile and gallbladder tissue level of a new quinolone, sparfloxacin, and its clinical efficacy on surgical infections. Chemotherapy (Basel) 39(Suppl. 4):620-632.
40. Thebault, J. J., G. Montay, M. Ebmeier, M. J. Douin, L. Millerioux, D. Chassard, and A. Mignot. 1990. Effect of food on the bioavailability of the new quinolone RP-64206, abstr. 1249, p. 294. In Program and abstracts of the 30th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
41. Tryba, M. 1990. Stress bleeding prophylaxis with sucralfate: pathophysiologic basis and clinical use. Scand. J. Gastroenterol. Suppl. 173:22-33.
42. Visser, M., M. Rozenberg, H. Beumer, I. Hoepelman, and J. Verhof. 1991. Comparative in vitro antibacterial activity of sparfloxacin, a new quinolone. Antimicrob. Agents Chemother. 35:858-868.
43. Wisemann, L. R., and D. Faulds. 1995. Cisapride - an updated review of its pharmacology and therapeutic efficacy as a prokinetic agent in gastrointestinal disorders. Drugs 47:116-152.
44. Wysowski, D. K., and J. Bacsanyi. 1996. Cisapride and fatal arrhythmia. N. Engl. J. Med. 25:290-291. (Letter.)